NRx Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $154.1M
- Price
- $3.56
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.42%
- Volume
- 615.3K
About
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Quick stats
Shares outstanding43.3M
Computed float31.0M
Float / shares71.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001719406
Websitehttps://www.nrxpharma.com
AI Summary
AI-generated1/42
majorbullishearnings
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
NRx Pharmaceuticals reported Q2 2026 financial results, highlighting a strengthened balance sheet with $26.7 million in cash following a $22.3 million public offering, sufficient to fund operations for at least one year. The net loss for the six months ended June 30, 2026, narrowed to $18.0 million from $23.1 million in the prior year period.
Regulatory progress was a major highlight, as the FDA completed its first-cycle review of the ANDA for preservative-free ketamine (NRX-100) with no drug-related major deficiencies. The company is currently manufacturing 5 million doses of launch stock in anticipation of 2026 commercialization.
Strategically, NRx was selected as prime contractor by DARPA for the SPARC-TMS Phase 2/3 trial of NRX-101, with anticipated non-dilutive funding exceeding $11.5 million. This partnership aims to expand the addressable market for NRX-101 to over 15 million Americans with treatment-resistant depression.
Red flags
- Net operating loss increased to $11.3 million from $7.6 million in the prior year period
- DARPA funding is anticipated but subject to completion of contracting